PDCD1 and neoplasm: The immunotherapy regimen, comprising a CD40 agonist, CTLA-4, and PD-1 checkpoint blocking antibodies (Figure 1D, Supplemental Figure 1C–D), was applied to assess its impact on tumor growth on the irradiated and a contralateral unirradiated tumor [32].